Can you provide the average price target for YS BIOPHARMA CO LTD stock?
9 analysts have analysed YS and the average price target is 4.26 USD. This implies a price increase of 317.5% is expected in the next year compared to the current price of 1.02.
YS BIOPHARMA CO LTD (YS) Forecast, Price Target & Analyst Ratings
NASDAQ:YS • KYG9845F1090
Current stock price
1.02 USD
+0.11 (+12.45%)
At close:
1.07 USD
+0.05 (+4.9%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for YS BIOPHARMA CO LTD (YS).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- N/A
- Period
- Q4 / 2024
- EPS Estimate
- -CN¥0.60
- Revenue Estimate
- 162.81M
Price Target Details & History
Consensus Price Target and Range
Mean target
$4.26
Upside
+ 317.50%
From current price of $1.02 to mean target of $4.26, Based on 9 analyst forecasts
Low
$3.13
Median
$4.26
High
$5.51
Price Target Revisions
1 Month
-3.47%
3 Months
-19.32%
Price Target Summary
9 Wall Street analysts provided a forecast for the next 12 months for YS. The average price target is 4.26 USD. This implies a price increase of 317.5% is expected in the next year compared to the current price of 1.02.
The average price target has been revised downward by 19.32% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
84.44%
YS was analyzed by 9 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about YS.
In the previous month the buy percentage consensus was at a similar level.
YS was analyzed by 9 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2023-11-13 | Noble Capital Markets | Initiate | Outperform |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- N/A
- Period
- Q4 / 2024
- EPS Estimate
- -CN¥0.60
- Revenue Estimate
- 162.81M
- Revenue Q2Q
- -76.31%
- EPS Q2Q
- N/A
- Number of Analysts
- 5
Next Earnings Revisions
Revenue (1 Month)
0.00%
Revenue (3 Months)
0.98%
EPS (1 Month)
0.00%
EPS (3 Months)
26.45%
Next Earnings Summary
The next earnings revenue estimate has been revised upward by 0.98% in the past 3 months.
Full Analyst Estimates 2024 - 2029
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 687.201M | 88.632M -87.10% | 112.79M 27.26% | 197.57M 75.17% | 1.88B 851.56% | 2.067B 9.95% | 2.538B 22.79% | |||
| EBITDA YoY % growth | N/A | 30.597M | -102.695M -435.63% | -22.739M 77.86% | -1.352M 94.05% | 16.108M 1,291.25% | N/A | N/A | N/A | |
| EBIT YoY % growth | -3.64K | -556.83K -15,197.53% | -139.382M -24,931.40% | -27.919M 79.97% | -6.768M 75.76% | 15.235M 325.11% | 537.75M 3,429.70% | 683.32M 27.07% | 1.038B 51.91% | |
| Operating Margin | N/A | N/A | -20.28% | -31.50% | -6.00% | 7.71% | 28.60% | 33.06% | 40.90% | |
| EPS YoY % growth | N/A | N/A | N/A | -0.34 | -0.11 66.94% | 0.04 132.93% | N/A | N/A | N/A |
All data in CNY
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q4 / 24 | Q1 / 25 | Q2 / 25 | Q3 / 25 | Q4 / 25 | |
|---|---|---|---|---|---|
| EPS Q2Q % growth | -0.60 | -0.70 | -0.37 67.19% | -0.29 65.25% | -0.06 89.66% |
| Revenue Q2Q % growth | 162.81M -76.31% | 181.09M | 186.76M 92.90% | 203.81M 23.54% | 232.54M 42.83% |
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -50.926M 63.46% | N/A | N/A | N/A | N/A |
All data in CNY
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
27.80%
EPS Next 5 Year
N/A
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
27.69%
Revenue Next 5 Year
85.19%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
41.56%
EBIT Next 5 Year
N/A
YS BIOPHARMA CO LTD / YS Forecast FAQ
Can you provide the consensus estimates for YS BIOPHARMA CO LTD next earnings?
The consensus EPS estimate for the next earnings of YS BIOPHARMA CO LTD (YS) is -0.6 USD and the consensus revenue estimate is 162.81M USD.
What is the expected long term growth rate for YS BIOPHARMA CO LTD (YS)?
The expected long term growth rate for YS BIOPHARMA CO LTD (YS) is 27.69%.